Aripiprazole

Generic Name: Aripiprazole

Brand Names: Abilify, Aripiprazole Mylan Pharma (previously Aripiprazole Pharmathen), Abilify Maintena, Aripiprazole Accord, Aripiprazole Sandoz, Aripiprazole Zentiva

Drug Type: Small Molecule

Chemical Formula: C_₂₃H_₂₇Cl_₂N_₃O_₂

CAS Number: 129722-12-9

Unique Ingredient Identifier: 82VFR53I78

Background: Aripiprazole is an atypical antipsychotic orally indicated for the treatment of schizophrenia, bipolar I, major depressive disorder, irritability associated with autism, and Tourette's. It is also indicated as an injection for agitation associated with schizophrenia or bipolar mania. Aripiprazole exerts its effects through agonism of dopaminergic and 5-HT1A receptors and antagonism of alpha-adrenergic and 5-HT2A receptors. Aripiprazole was given FDA approval on November 15, 2002.

Indication: Aripiprazole is indicated for the treatment of acute manic and mixed episodes associated with bipolar I disorder, irritability associated with autism spectrum disorder, schizophrenia, and Tourette's disorder. It is also used as an adjunctive treatment of major depressive disorder.[L45859 An injectable formulation of aripiprazole is indicated for agitation associated with schizophrenia or bipolar mania. Finally, an extended-release, bimonthly injection formulation of aripiprazole is indicated for the treatment of adult schizophrenia and maintenance therapy for adult bipolar I disorder.

Associated Conditions: Agitation, Bipolar 1 Disorder, Irritability, Major Depressive Disorder (MDD), Mixed manic depressive episode, Psychosis, Psychotic Depression, Schizophrenia, Tourette's Disorder (TD), Acute Manic episode

Associated Therapies: Monotherapy

Clinical Trials

The Combination of Aripiprazole and Antidepressants in Psychotic Major Depression

Phase 3

Completed

Conditions: Psychotic Depression

Interventions: Drug: Aripiprazole

First Posted Date: 2007-11-09

Last Posted Date: 2012-08-20

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 16

Registration Number: NCT00556140

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Evaluation of the Strategies of Switching Schizophrenia Patients to Aripiprazole From Other Antipsychotic Agents

Phase 4

Completed

Conditions: Schizoaffective Disorder
DSM-IV Schizophrenia

Interventions: Drug: Aripiprazole

First Posted Date: 2007-10-17

Last Posted Date: 2012-05-17

Lead Sponsor: National Taiwan University Hospital

Target Recruit Count: 79

Registration Number: NCT00545467

Locations: 🇨🇳
Department of Psychiatry, National Taiwan University Hospital, Taipei, Taiwan

Health Evaluation of Abilify Long-term Therapy

Phase 4

Completed

Conditions: Schizophrenia
Schizoaffective Disorder

First Posted Date: 2007-08-24

Last Posted Date: 2009-12-16

Lead Sponsor: Taiwan Otsuka Pharm. Co., Ltd

Target Recruit Count: 245

Registration Number: NCT00520650

Locations: 🇨🇳
Buddhist Tzu Chi General Hospital, Hualien, Taiwan
🇨🇳
Changhua Christian Hospital, Changhua, Taiwan
🇨🇳
Cardinal Tien Hospital Hsin Chu Mercy Branch, Hsinchu, Taiwan

and more 6 locations

A Phase 4 Study to Assess the Effects of Aripiprazole Versus Other Atypical Antipsychotics in the Treatment of Schizophrenic Patients With Metabolic Syndrome

Phase 4

Terminated

Conditions: Schizophrenia
Metabolic Syndrome

Interventions: Drug: Continued Antipsychotic (Risperidone or Quetiapine or Olanzapine)
Drug: Aripiprazole

First Posted Date: 2007-07-27

Last Posted Date: 2013-12-13

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 125

Registration Number: NCT00508157

Locations: 🇹🇷
Local Institution, Izmir, Turkey

Aripiprazole Treatment for Methamphetamine Dependence Among High-risk Individuals

Phase 2

Completed

Conditions: Substance Abuse
HIV Infections

Interventions: Drug: Placebo
Drug: Aripiprazole

First Posted Date: 2007-07-06

Last Posted Date: 2014-03-24

Lead Sponsor: San Francisco Department of Public Health

Target Recruit Count: 90

Registration Number: NCT00497055

Locations: 🇺🇸
San Francisco Department of Public Health, AIDS Office, San Francisco, California, United States

Aripiprazole Augmentation of Antidepressants in PTSD

Phase 2

Completed

Conditions: PTSD

Interventions: Drug: Placebo
Drug: Aripiprazole

First Posted Date: 2007-06-21

Last Posted Date: 2015-03-31

Lead Sponsor: Durham VA Medical Center

Target Recruit Count: 14

Registration Number: NCT00489866

Locations: 🇺🇸
Durham VAMC 508 Fulton Street, Durham, North Carolina, United States

ABLE: Abilify in Bipolar Disorder for Long-term Effectiveness

Phase 4

Completed

Conditions: Bipolar Disorder

Interventions: Drug: aripiprazole
Drug: valproate
Drug: placebo

First Posted Date: 2007-06-11

Last Posted Date: 2022-03-31

Lead Sponsor: Korea Otsuka International Asia Arab

Target Recruit Count: 127

Registration Number: NCT00484471

Locations: 🇨🇳
Changhua Chrisitian Hospital, Changhua, Taiwan
🇨🇳
Jia-Nan Mental Hospital, Tainan, Taiwan
🇭🇰
Castle Peak Hospital, Tuen Mun, Hong Kong

and more 10 locations